[Detection of premature rupture of fetal membranes by determining insulin-like-growth-factor-binding protein-1].
In a clinical trial we examined the suitability of commercially available membrane immune assay for providing evidence of amniotic fluid. 150 amniotic fluid samples won either by amniotomy or amniocentesis were examined in 10 runs; 50 women without any signs of ruptured membranes served as a control group. Evidence of insulin-like growth-factor binding protein with a sensitivity of 97% and a specificity of 100% demonstrated that this test appears to give reliable proof of amniotic fluid. However, a specificity of 100% has to be critically investigated.
Woltmann
W
W
Abteilung Geburtsmedizin, Virchow-Klinikum, Medizinische Fakultät, Humboldt-Universität zu Berlin.
Hofstaetter
C
C
Dudenhausen
J W
JW
D000649:Amniocentesis; D000653:Amniotic Fluid / Q000737:chemistry*; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000175:diagnosis*; D005865:Gestational Age; D006801:Humans; D007118:Immunoassay; D007231:Infant, Newborn; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000032:analysis*; D011247:Pregnancy; D012016:Reference Values; D012680:Sensitivity and Specificity
D018970:Insulin-Like Growth Factor Binding Protein 1